role of toclizumab in a patient with ARDS developed due to covid 19: (A) it acts by halting lysogenic phase of corona virus, (B) it stops the lung parenchymal damge by the virus, (C) it is a IL-6 receptor inhibitor, (D) all the above
Answer is C. Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor, has been proposed to mitigate the cytokine storm syndrome associated with severe COVID-19. We aimed to investigate the association between tocilizumab exposure and hospital-related moality among patients requiring intensive care unit (ICU) suppo for COVID-19. ref : www.ncbi.gov